Antiphospholipid antibodies: Laboratory and pathogenetic aspects

Vlachoyiannopoulos, PG; Samarkos, M; Sikara, M; Tsiligros, P

dc.contributor.author	Vlachoyiannopoulos, PG	en
dc.contributor.author	Samarkos, M	en
dc.contributor.author	Sikara, M	en
dc.contributor.author	Tsiligros, P	en
dc.date.accessioned	2014-03-01T11:46:17Z
dc.date.available	2014-03-01T11:46:17Z
dc.date.issued	2007	en
dc.identifier.issn	1040-8363	en
dc.identifier.uri	https://dspace.lib.ntua.gr/xmlui/handle/123456789/37770
dc.subject	activated protein C resistance	en
dc.subject	anticardiolipin antibodies	en
dc.subject	antiphospholipid antibodies	en
dc.subject	antiphospholipid syndrome	en
dc.subject	CD40	en
dc.subject	endothelial cells	en
dc.subject	fibrinolysis	en
dc.subject	hypercoagulable state	en
dc.subject	lupus coagulation inhibitor	en
dc.subject	systemic lupus erythematosus	en
dc.subject	thrombophilia	en
dc.subject.classification	Medical Laboratory Technology	en
dc.subject.other	SYSTEMIC-LUPUS-ERYTHEMATOSUS	en
dc.subject.other	ACTIVATED PROTEIN-C	en
dc.subject.other	KAOLIN CLOTTING TIME	en
dc.subject.other	ANTI-BETA(2)-GLYCOPROTEIN I ANTIBODIES	en
dc.subject.other	MONOCLONAL ANTICARDIOLIPIN ANTIBODIES	en
dc.subject.other	ANTI-PROTHROMBIN ANTIBODIES	en
dc.subject.other	PARTIAL THROMBOPLASTIN TIME	en
dc.subject.other	VIPER VENOM TIME	en
dc.subject.other	HUMAN ENDOTHELIAL-CELLS	en
dc.subject.other	FACTOR-V-LEIDEN	en
dc.title	Antiphospholipid antibodies: Laboratory and pathogenetic aspects	en
heal.type	other	en
heal.language	English	en
heal.publicationDate	2007	en
heal.abstract	Antiphospholipid antibodies ( aPL) constitute a heterogeneous group of autoantibodies that share the ability to bind phospholipids ( PL) alone, protein- PL complexes, or PL-binding proteins. They have been detected in isolation, in association with autoimmune diseases such as systemic lupus erythematosus ( SLE), and during the course of different infections. aPL have been associated with an array of clinical manifestations in virtually every organ, although deep vein and arterial thrombosis as well as pregnancy morbidity are predominant. The co-occurrence of these clinical findings with aPL constitutes the so-called antiphospholipid syndrome ( APS). aPL can be detected by immunological methods [ e. g., anticardiolipin antibodies ( aCL)] or by functional methods that exploit the effect of aPL on blood coagulation [ lupus anticoagulant ( LA)]. Since aPL are heterogeneous, numerous immunological and coagulation assays have been developed. These assays have not been fully standardized, and, therefore, problems such as high interlaboratory variation are relatively frequent. Recently, recommendations have been published regarding LA and aCL testing. Not all aPL are pathogenic. However, when they are not associated with infections, they have a role in the pathogenesis of APS. Clinical and experimental data have shown that aPL exert their pathogenic activity by interfering with the function of coagulation factors, such as thrombin and factors X, XI and XII, and with the function of anticoagulant proteins of the protein C system. In addition, aPL interaction with platelets and endothelial cells induces a pro- adhesive activated phenotype.	en
heal.publisher	TAYLOR & FRANCIS INC	en
heal.journalName	CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES	en
dc.identifier.isi	ISI:000247564000003	en
dc.identifier.volume	44	en
dc.identifier.issue	3	en
dc.identifier.spage	271	en
dc.identifier.epage	338	en